Identification of New Colorectal Cancer Genes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00582335

Enrollment

337

Registered

2007-12-28

Start date

1998-02-10

Completion date

2021-12-17

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal cancer, Genetic testing, Genetic mutations

Brief summary

The purpose of this study is to define new genes for family risks of developing colon cancer.

Detailed description

Colorectal cancer is one of the most significant causes of cancer morbidity and mortality in the United States. In 1997, approximately 130,000 men and woman were diagnosed with colorectal cancer (fourth most common cancer site) and approximately 55,000 died of this disease (second most common cause of cancer deaths); (Cancer Facts & Figures, 1997). Genetic factors clearly contribute to the etiology of colorectal cancer. Because there is evidence to suggest genetically determined susceptibility to colorectal cancer exists in a proportion of newly diagnosed cases each year, we are conducting a study to identify new genes that are associated with an increased susceptibility to familial colorectal cancer by analysis of families with a clustering of colorectal cancers.

Interventions

None listed

Study design

Observational model

FAMILY_BASED

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age 18 years or greater * Able to provide informed consent * Any family in which a minimum of two first-degree relatives either are, or have previously been, affected with primary colorectalcancer. These minimum inclusion criteria must be met within three generations of the proband or kindreds in which colorectal cancer and lymphoma or renal cell cancer are present or in kindreds in which lymphoma alone or lymphoma and renal cell cancer are present

Exclusion criteria

* Age less than 18 years * Family not at increased risk for familial colorectal cancer (see Section 4.1) * Family with a hereditary polyposis syndrome (e.g. classic FAP) * Not able to provide informed consent

Design outcomes

Primary

Measure	Time frame
Evidence of mutations in selected candidate genes	10 years 10 months

Countries

United States

Outcome results